♥ HF Guideline NavigatorESC 2026

2

2 Introduction

Pages 9–15 · open in PDF

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 9 · PDF

Levels of evidence—therapy and prevention

Definition Conclusive evidence, usually from at least two adequately powered randomized controlled trialsa free of major bias, with substantial evidence against the play of chance when combined in a meta-analysis (e.g., P <0.005 for superiority).b

Suggestive evidence from at least one adequately powered randomized controlled trial free of major bias, or a meta-analysis of such randomized controlled trials, with some evidence against the play of chance (e.g., P <0.05 for superiority).c

Limited evidence from at least two adequately powered non-randomized studies with careful control of major sources of bias and substantial evidence against the play of chance (e.g., P <0.005 for superiority),b or from a meta-analysis of small, underpowered randomized controlled trials with some evidence against the play of chance (e.g., P <0.05 for superiority).c

Preliminary evidence from non-randomized studies without careful control of major sources of bias, a single small, underpowered randomized controlled trial, or expert consensus.

Exceptionally, level of evidence A can be considered if (1) there is a single very large randomized controlled trial that provides convincing evidence across a wide range of patients that is already widely accepted by most practitioners, or (2) the effects of the intervention are clinically obvious; in either case, over 90% of voting guideline task force members need to agree with level of evidence A. b Studies do not need to individually show substantial evidence against the play of chance (e.g. a P-value of <.005 for superiority) if a meta-analysis of these studies provides such evidence. c Studies do not need to individually show some evidence against the play of chance (e.g. a P-value of <.05 for superiority) if a meta-analysis of these studies provides such evidence.

Prediction model (including diagnostic and prognostic models)

Conclusive evidence of adequate diagnostic ability from at least two high-quality studies

Conclusive evidence of adequate predictive ability from at least one high-quality derivation study, and two or more external validation studies of at least moderate quality.

Suggestive evidence of adequate diagnostic ability from a single high-quality or at least two moderate-quality studies.

Suggestive evidence of adequate predictive ability from one or more derivation and one or more external validation studies of at least moderate quality.

Preliminary evidence of adequate diagnostic ability from a single moderate-quality study, any number of low-quality studies, or expert consensus.

Preliminary evidence of adequate predictive ability from a derivation study of at least moderate quality, but with external validation absent or in a low-quality study, or a derivation study of low quality (irrespective of external validation).

Table 3 Levels of evidence—diagnostic tests and prediction models

2. Introduction In these guidelines, we have redefined the classification of heart failure (HF) compared with the definition used in the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure,3 and provided a simple definition that we believe will translate into everyday clinical practice. As early detection of HF is increasingly important, we have, in alignment with the

2022 AHA/ACC/HFSA Guideline for the management of heart failure,4 also included risk factors and early signs of HF into the staging of HF. An updated classification for the treatment of HF has also been added, which emphasizes foundational and additional medical therapies, as well as interventional therapies. Figure 1 provides an overview of current management recommendations for HF. Since the publication of the 2021 ESC Guidelines for the diagnosis and treatment of acute and

Page 10 · PDF

       

      ‡€‘€

‰‡“€‚ ”  €‚€‚

”€†ƒ€‚‡€†€ƒ€‚    € €†‘

  ‚„‚€‚Ž

  ‡’‚ ‡        ‡€†‚€ „­

 ”† •€‡‚‰  ‚­‰  ‰

‡€„‡‡­€‚†­

     

‡€’„’ ’‚€€‚ ­€€€‚ƒ €„  ‚€€‚†

Figure 1 Central illustration. Management of heart failure. ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; AS, aortic stenosis; AV, atrioventricular; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, heart rate; ICD, implantable cardioverter-defibrillator; ISDN, isosorbide dinitrate; IV, intravenous; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; TEER, transcatheter edge-to-edge repair; NYHA, New York Heart Association; SAVR, surgical aortic valve replacement; SGLT2-I, sodium–glucose co-transporter 2 inhibitor; SR, sinus rhythm; TAVI, transcatheter aortic valve implantation. Green colour refers to Class I recommendation. Yellow colour refers to Class IIa recommendation. Orange colour refers to Class IIb recommendation. aAn ARB is recommended in patients with symptomatic HFrEF if they are unable to tolerate an ACE-I or ARNI. bNo large prospective randomized controlled trial has been performed on the use of beta-blockers, ACE-I/ ARNI/ARB exclusively in patients with LVEF 41%–49%. cClass of recommendation for ICD differs according to ischaemic vs nonischaemic aetiology. dClass of recommendation for CRT differs according to QRS duration and morphology (see Figure 10 and Recommendation Table 7). eCriteria for advanced HF are listed in Table 14. fIndications and contraindications for heart transplantation are listed in Table 17. gIndications and contraindications for LVAD implantation are listed in Table 16. hPredominantly obstructive sleep apnoea.

chronic heart failure3 and the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure,5 new guidance for interpretation of evidence has been published by the ESC.1,2 Consequently, all recommendations, new and old, have been regraded to comply with the revised ESC evidence grading system. For recommendations with more than one outcome, e.g. cardiovascular (CV) death and HF hospitalization (HFH), the wording reflects

whether both outcomes were individually significant (‘AND’) or the outcome was a composite (‘OR’). For each topic, we have considered age and sex differences and included these in the recommendations, if deemed clinically relevant. Since the publication of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure,3 several relevant guidelines on specific topics, such as cardio-oncology,6

Page 11 · PDF

pregnancy,7 myocarditis,8 valvular heart disease,9 and chronic coronary syndrome,10 have been published. In the current guidelines, these topics are not addressed in detail, and we refer to the specific guidelines for each topic.

New concepts HFrEF has been expanded to include LVEF up to 50% HFmrEF has been removed

Decompensated HF replaces acute HF Stages of HF (A–D) ranging from risk factors to advanced HF have been adopted New classifications for medical and interventional therapy have been introduced HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction.

New recommendations Classa

Review of the proportion of RV pacing should be considered in all patients with CIED and de novo or worsening HFrEF.

Electrical cardioversion as a diagnostic tool may be considered in patients with persistent AF where there is uncertainty about the value of sinus rhythm restoration on symptoms or to assess improvement in left ventricular function.

Uptitration of FMT at least every 1–2 weeks in patients with HF, guided by symptoms, vital signs, and laboratory findings, to achieve optimal target doses shown to be efficacious in RCTs is recommended to reduce the risk of HFH or death.

Continuation of FMT at the highest tolerated doses is recommended in all patients with HF, including those who become asymptomatic or with LVEF improvement, in order to reduce the risk of HFH and death.

ACE-I/ARB/ARNI may be considered in patients with symptomatic HFpEF to reduce the risk of HFH.

Initiation of FMT and planning for CRT implantation may be considered simultaneously in patients with symptomatic HFrEF, an LBBB with QRS ≥150 ms, and LVEF ≤35% to improve symptoms and reduce morbidity and death, although reassessment

Recommendations Prevention of heart failure—Section 4 Counselling on healthy lifestyle choices including maintaining a healthy weight, consuming a well-balanced diet, avoiding sedentary behaviour, abstaining from smoking and heavy alcohol consumption, as well as counselling against the use of drugs such as cocaine, amphetamines, and anabolic steroids, is recommended for all patients with stage A or B HF to reduce the risk of HF progression. A GLP-1 RA should be considered in patients with T2DM and at least one other additional CV risk factor to reduce the risk of HF or CV death. An ACE-I or ARB (if intolerant to ACE-I) is recommended in patients with stage B HF and LVEF ≤40% to reduce the risk of HFH and death. A beta-blocker is recommended in patients with stage B HF and LVEF <50% to reduce the risk of HFH or death. Eplerenone is recommended in patients after myocardial infarction with LVEF ≤40% with signs of HF or diabetes to reduce the risk of HFH or death. Diagnosis of chronic heart failure—Section 5 Initial diagnostic testing with serum and urine immunofixation, serum free light chains assay, and DPD/PYP/HMDP bone scintigraphy is recommended in patients with HF and a suspicion of cardiac amyloidosis. Genetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, prognostication, therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of their relatives who would otherwise be enrolled into long-term surveillance. 18F-FDG-PET scanning should be considered for the diagnostic work-up in patients with cardiomyopathy in whom cardiac sarcoidosis is suspected.

Management of chronic heart failure—Section 6

Gradual discontinuation of FMT under frequent clinical, laboratory, and imaging surveillance may be considered in highly selected patients who are asymptomatic with complete normalization of LV function and volume as well as natriuretic peptide levels after specific treatment of reversible causes of HF, in order to accommodate patient preference.

of LVEF should be conducted prior to CRT implantation. Continued

In the 2026 ESC Guidelines for the management of heart failure, some new concepts compared with the 2021 version are introduced in addition to the recommendations listed below. These changes will have impact on some recommendations, specifically concerning guideline-recommended treatment of HF because we have changed the classification of HF based on left ventricular ejection fraction (LVEF). For details of the new concepts, see Sections 3, 6, and 7. Table 4 provides an overview of new concepts. Table 5 highlights the new recommendations and Table 6 the revised recommendations, included in this document.

HFpEF includes LVEF from 50% and above

Page 12 · PDF

Decompensated heart failure—Section 7 IIb

In-hospital initiation of SGLT2-I is recommended in patients with DHF after initial stabilization to improve QoL and congestion symptoms and reduce the risk of HFH.

A multidisciplinary Shock Team is recommended in potential candidates for temporary MCS to guide the device selection (modality and type) based on patient and HF characteristics.

Temporary MCS with a microaxial flow pump should be considered in selected patients with cardiogenic shock caused by ST-elevation MI with LV systolic dysfunction and no risk of hypoxic brain injury in order to reduce the risk of death.

Temporary MCS should be considered in patients with mechanical complications related to MI as a bridge to definitive treatment.

Temporary MCS is not recommended in unselected patients with cardiogenic shock caused by acute MI, due to risk of harm.

Cardiac rehabilitation is recommended in patients with an LVAD to improve functional capacity and QoL.

Cardiac rehabilitation should be considered in patients with DHF, as soon as safely possible, to improve functional capacity and QoL.

Proactive discussion regarding HF trajectory, goals of care, and advance care planning is recommended in patients with advanced HF to facilitate communication on end of life and QoL.

Access to an integrated HF palliative care multidisciplinary team is recommended for patients in an advanced HF stage to improve QoL and reduce symptom burden.

Advanced heart failure—Section 8 Early consultation with an advanced HF centre is recommended in patients with advanced HF or at risk of advanced HF, who are motivated and do not have absolute contraindications for heart transplantation or durable MCS, in order to evaluate candidacy. Downtitration or discontinuation of beta-blockers or ivabradine should be considered in selected patients with advanced HFrEF and evidence of organ hypoperfusion, despite initial treatment, to increase cardiac output and improve symptoms. Histopathological examination of explanted heart tissue from LVAD or heart transplantation surgery should be considered in patients with non-ischaemic HF to identify an aetiological diagnosis that may be treatable or facilitate family screening. Cardiovascular comorbidities—Section 9 Atrioventricular node ablation combined with CRT should be considered in patients with severely symptomatic permanent AF and poor rate control despite medical therapy and at least one HFH to reduce symptoms, physical limitations, recurrent HFH and death. Intravenous amiodarone or digoxin may be considered in haemodynamically unstable patients with HFrEF and AF to stabilize the patient and achieve acute control of heart rate. Non-cardiovascular comorbidities—Section 10 Semaglutide or tirzepatide should be considered for patients with symptomatic HF, LVEF ≥45%, and BMI ≥30 kg/m2, regardless of diabetes status, to reduce body weight, and improve exercise capacity and QoL. Bariatric surgery may be considered in obese patients with HF and a BMI ≥35 kg/m2 to reduce body weight when repetitive and structured lifestyle changes combined with weight-reducing medications do not result in maintained weight loss. Adaptive servo-ventilation may be considered in patients with HFrEF and sleep-disordered breathing with predominant obstructive sleep apnoea to improve sleep quality, health-related QoL, and symptoms. Assessment of anxiety, depression and frailty should be considered in patients with HF to support the development of personalized care plans and to identify factors that may contribute to adverse outcomes. Multidisciplinary management of heart failure—Section 11 Personalized exercise training, in the context of multidisciplinary exercise-based cardiac rehabilitation, is recommended for all stable patients, unless there are specific contraindications, in order to improve exercise capacity, and QoL, and reduce the risk of all-cause hospitalization. Personalized exercise training outside exercise-based cardiac rehabilitation is recommended for all stable patients on a long-term basis, unless there are specific contraindications, in order to improve exercise capacity and QoL, and reduce the risk of all-cause hospitalization.

Urinary Na+-guided diuretic therapy may be considered during the first days of treatment of patients with DHF to improve natriuresis and diuresis.

Page 13 · PDF

Pre-conception care and counselling is recommended for patients with HF to facilitate decision-making surrounding HF treatments, pregnancy, contraception, pre-implantation genetic screening, and assisted reproductive therapies. In pregnant women with HFrEF, it is recommended that non-selective beta-blockers are switched to beta1-selective blockers (metoprolol, bisoprolol) with close mother and foetus monitoring to reduce the risk of adverse foetal events and a lower birth

weight. ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2-Is are not recommended during pregnancy due to the risk of foetotoxicity or teratogenicity.

Recommendations in 2021 version

Recommendations in 2026 version

Prevention of heart failure—Section 4 Treatment of hypertension is recommended to prevent or delay the onset of HF, and to prevent HF hospitalizations.

Strict blood pressure control (systolic blood I

pressure target <130 mmHg) is recommended in patients with hypertension or stage B HF to reduce the risk of HF.

Diagnosis of chronic heart failure—Section 5 CMR is recommended for the assessment of myocardial structure and function in those with

Contrast-enhanced CMR is recommended in patients with suspected cardiomyopathy, or where

poor echocardiographic acoustic windows.

the underlying aetiology of HF is uncertain if

CMR is recommended for the characterization of

further characterization is likely to add value to patient care.

myocardial tissue in suspected infiltrative disease, Fabry disease, inflammatory disease (myocarditis), LV non-compaction, amyloid, sarcoidosis, iron

overload/haemochromatosis. CMR with LGE should be considered in DCM to distinguish between ischaemic and non-ischaemic myocardial damage. Invasive coronary angiography is recommended in patients with angina despite pharmacological therapy or symptomatic ventricular arrhythmias.

Invasive coronary angiography is recommended in I

patients with HF, angina, and high probability of obstructive CAD who are potential candidates for revascularization.

Invasive coronary angiography may be considered

Invasive coronary angiography should be

in patients with HFrEF with an intermediate to high pre-test probability of CAD and the presence of ischaemia in non-invasive stress tests.

considered in patients with HFrEF and high IIb

pre-test likelihood of obstructive CAD, taking into account the risk-to-benefit ratio of the procedures and potential revascularization strategies.

Management of chronic heart failure—Section 6 An MRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death.

An MRA may be considered for patients with HFmrEF to reduce the risk of HF hospitalization

An MRA (sMRA for HFrEF and sMRA/nsMRA for HFpEF) is recommended in patients with symptomatic HF independent of LVEF to reduce the risk of HFH or CV death.

18F-FDG-PET, 18F-fluorodeoxyglucose-positron emission tomography; ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; BTB, bridge to bridge; BTC, bridge to candidacy; BTD, bridge to decision; BTR, bridge to recovery; BTT, bridge to transplantation; CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy; CV, cardiovascular; DHF, decompensated heart failure; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; FMT, foundational medical therapy; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure; HFH, heart failure hospitalization; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HMDP, hydroxymethylene diphosphonate; LBBB, left bundle branch block; LV, left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; PYP, pyrophosphate; QoL, quality of life; RCT, randomized controlled trial; RV, right ventricular; SGLT2-I, sodium–glucose co-transporter 2 inhibitor; T2DM, type 2 diabetes mellitus. a Class of recommendation. b Level of evidence.

Specific conditions—Section 12

Page 14 · PDF

Digoxin may be considered in patients with

A cardiac glycoside (digoxin or digitoxin) should be

symptomatic HFrEF in sinus rhythm despite treatment with an ACE-I (or ARNI), a beta-blocker and an MRA, to reduce the risk of hospitalization

considered in patients with symptomatic HFrEF IIb

with LVEF ≤40%, despite optimal FMT, to reduce the risk of HFH.

(both all-cause and HF hospitalizations). Vericiguat may be considered in patients in NYHA

Vericiguat may be considered in patients with

classes II–IV who have had worsening HF despite

symptomatic HFrEF and LVEF <45% despite IIb

treatment with optimal FMT to reduce the risk of HFH and CV death.

HF hospitalization. [In patients with HFrEF according to the 2021 classification.] CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular

CRT, rather than RV pacing, should be considered I

in patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular

pacing for high degree AV block in order to reduce

pacing for high-degree AV block in order to reduce

morbidity. This includes patients with AF.

the risk of HFH and death.

Decompensated heart failure—Section 7 Combination of a loop diuretic with thiazide-type

The addition of short-term intravenous

diuretic should be considered in patients with resistant oedema who do not respond to an increase in loop diuretic doses.

acetazolamide or oral hydrochlorothiazide should IIa

be considered in patients with fluid overload previously treated with loop diuretics, to reduce congestion.

IABP is not routinely recommended in post-MI cardiogenic shock.

Short-term MCS should be considered in patients with cardiogenic shock as a BTR, BTD, BTB. Further indications include treatment of the cause

IABP is not recommended in unselected patients with cardiogenic shock, due to the lack of effect. Temporary MCS should be considered in selected

patients with HF-related haemodynamic instability as a BTR, BTD, BTB, BTC, or BTT.

of cardiogenic shock or long-term MCS or transplantation Advanced heart failure—Section 8 Continuous inotropes and/or vasopressors may be

Continuous inotropes should be considered in

considered in patients with low cardiac output and

patients with advanced HFrEF, low cardiac output,

evidence of organ hypoperfusion as bridge to MCS or heart transplantation.

and evidence of hypoperfusion or end-organ dysfunction, as BTD, BTT, or as bridge to durable MCS, to increase cardiac output and improve symptoms.

Long-term MCS should be considered in patients

Durable MCS (LVAD) is recommended in selected

with advanced HFrEF despite optimal medical and device therapy, not eligible for heart

patients with advanced HFrEF, despite FMT and GDIT, as BTT, BTC, BTR, or as destination therapy

transplantation or other surgical options, and

to improve symptoms and reduce the risk of death.

without severe right ventricular dysfunction, to reduce the risk of death and improve symptoms. Long-term MCS should be considered in patients with advanced HFrEF refractory to optimal medical and device therapy as a bridge to cardiac transplantation in order to improve symptoms, reduce the risk of HF hospitalization and the risk of

premature death. Cardiovascular comorbidities—Section 9 Beta-blockers should be considered for short- and long-term rate control in patients with HF and AF.

Beta-blockers are recommended in stable patients with HFrEF and AF as first-line therapy for shortand long-term rate control. Continued

treatment with an ACE-I (or ARNI), a beta-blocker and an MRA to reduce the risk of CV mortality and

Page 15 · PDF

In cases of a clear association between paroxysmal or persistent AF and worsening of HF symptoms, which persist despite MT, catheter ablation should be considered for the prevention or treatment of AF.

Catheter ablation for AF should be considered in IIa

angina, despite FMT for HF and antianginal drugs, to relieve symptoms.

antianginal drugs. Aortic valve intervention, TAVI or SAVR, is

Aortic valve intervention, SAVR or TAVI, is

recommended in patients with HF and severe

recommended in patients with severe aortic

high-gradient aortic stenosis to reduce mortality and improve symptoms.

Percutaneous edge-to-edge mitral valve repair should be considered in carefully selected patients

Mitral transcatheter edge-to-edge repair is recommended in haemodynamically stable,

with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are symptomatic despite

stenosis and HF to improve symptoms and reduce the risk of death.

symptomatic patients with HFrEF and persistent IIa

severe secondary mitral regurgitation despite optimized FMT and CRT if indicated, who fulfil

OMT and who fulfil criteria for achieving a

specific clinical and echocardiographic criteria, in

reduction in HF hospitalizations.

order to reduce the risk of HFH and improve QoL.

Multidisciplinary management—Section 11 Monitoring of pulmonary artery pressure using a wireless haemodynamic monitoring system may be considered in symptomatic patients with HF in order to improve clinical outcomes.

Remote haemodynamic monitoring of PA pressure IIb

should be considered in symptomatic patients with HF, NYHA class III and an HFH in the past 12 months in order to reduce the risk of HFH.

Specific conditions—Section 12

or II symptoms to reduce symptoms, CV

hospitalization and mortality.

variant or wild-type transthyretin cardiac amyloidosis and NYHA class I–III is recommended to reduce progression of symptoms and the risk of

Tafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and

Treatment with a TTR silencer (vutrisiran) or stabilizer (tafamidis or acoramidis) for patients with

CV hospitalization and all-cause death.

mortality. ACE-I angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARNI, angiotensin receptor–neprilysin inhibitor; AV, atrioventricular; BTC, bridge to candidacy; BTD, bridge to decision; BTR, bridge to recovery; BTT, bridge to transplantation; CAD, coronary artery disease; CCS, chronic coronary syndrome; CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; CV, cardiovascular; DCM, dilated cardiomyopathy; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hTTR-CA, hereditary transthyretin cardiac amyloidosis; IABP, intra-aortic balloon pump; LGE, late gadolinium enhancement; LV, left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; MT, medical therapy; nsMRA, non-steroidal mineralocorticoid receptor antagonist; NYHA, New York Heart Association; OMT, optimal medical therapy; PA, pulmonary artery; QoL, quality of life; RV, right ventricular; SAVR, surgical aortic valve replacement; sMRA, steroidal mineralocorticoid receptor antagonist; TAVI, transcatheter aortic valve implantation; TTR, transthyretin; wtTTR-CA, wild-type transthyretin cardiac amyloidosis. a Class of recommendation. b Level of evidence.

3. Definition, epidemiology, and classifications 3.1. Definition of heart failure Heart failure is a clinical syndrome comprising signs and/or symptoms caused by structural and/or functional abnormalities of the heart that result in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise.11 In addition to the subjective symptoms of HF, clinically assessed objective evidence of cardiogenic pulmonary and/or systemic congestion and diagnostic supportive tests are needed to reach the diagnosis (see Section 5).11

People who are in asymptomatic stages are not included under the above definition as having HF. They are defined as being at risk for HF (stage A) or having pre-HF (stage B) (see Section 3.3). Identification of the aetiology of the underlying cardiac dysfunction is not included in the definition of HF, although determining aetiology is clinically important as the specific pathology can determine subsequent treatment and prognosis. Specific investigations needed to identify underlying aetiologies are described in Section 5.

3.2. Epidemiology of heart failure The prevalence of HF is estimated to be 1%–3% in the general adult population, with significant geographical, age- and sex-related

Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I

and coronary anatomy suitable for revascularization, despite OMT including

to improve QoL and reduce the risk of HFH or death. Coronary revascularization is recommended in patients with HF, obstructive CAD, and persistent

Coronary revascularization should be considered to relieve persistent symptoms of angina (or an angina-equivalent) in patients with HFrEF, CCS,

selected patients with symptomatic AF and HFrEF